Pro108Ser mutation of SARS-CoV-2 3CL(pro) reduces the enzyme activity and ameliorates the clinical severity of COVID-19

Recently, an international randomized controlled clinical trial showed that patients with SARS-CoV-2 infection treated orally with the 3-chymotrypsin-like protease (3CL(pro)) inhibitor PF-07321332 within three days of symptom onset showed an 89% lower risk of COVID-19-related hospital admission/ dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Kodai, Kabe, Yasuaki, Uchiyama, Susumu, Iwasaki, Yuka W., Ishizu, Hirotsugu, Uwamino, Yoshifumi, Takenouchi, Toshiki, Uno, Shunsuke, Ishii, Makoto, Maruno, Takahiro, Noda, Masanori, Murata, Mitsuru, Hasegawa, Naoki, Saya, Hideyuki, Kitagawa, Yuko, Fukunaga, Koichi, Amagai, Masayuki, Siomi, Haruhiko, Suematsu, Makoto, Kosaki, Kenjiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789791/
https://www.ncbi.nlm.nih.gov/pubmed/35079088
http://dx.doi.org/10.1038/s41598-022-05424-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789791/
https://www.ncbi.nlm.nih.gov/pubmed/35079088
http://dx.doi.org/10.1038/s41598-022-05424-3

Ejemplares similares